Novo Nordisk signs pact with Vivani for long-lasting semaglutide implant - Pharmaceutical Technology

Novo Nordisk has partnered with Vivani Medical to develop a long-acting semaglutide implant, a move that could eventually offer an alternative to weekly GLP-1 injections. The pact signals major industry investment in sustained-release peptide delivery platforms for GLP-1 therapeutics.

What the deal covers

According to Pharmaceutical Technology, the agreement centers on Vivani's implant technology as a potential vehicle for extended delivery of semaglutide, the active ingredient in Ozempic and Wegovy. The goal is to reduce dosing frequency by embedding the peptide in a depot-style device that releases drug over a prolonged period.

Few technical specifics have been disclosed publicly. The collaboration is early-stage, and any implant product would need to clear preclinical validation, clinical trials, and regulatory review before reaching patients.

Why it matters for peptide delivery

Sustained-release delivery is one of the more active frontiers in GLP-1 development. Weekly subcutaneous injections have driven mass adoption, but adherence, supply constraints, and dosing burden remain open problems. An implant could, in theory, smooth pharmacokinetics and eliminate patient-administered shots, but the engineering challenges are nontrivial.

• Peptides like semaglutide are fragile molecules; stabilizing them inside an implant for weeks or months is technically demanding.
• Dose titration and emergency withdrawal become harder when the drug is embedded in a device rather than in a syringe.
• Regulatory pathways for peptide implants are less established than for injectable pens.

Preliminary and worth watching

This development is preliminary. The partnership is a signal of intent, not a product. SavePeptides will continue to track whether the Vivani platform can demonstrate stable semaglutide release and acceptable safety in preclinical models before any human trials are announced.